
Olema Oncology (OLMA) announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive, or ER+, human epidermal growth factor receptor 2-negative, or HER2-, breast cancer models. The
Compare up to 40 stocks
Compared Stocks: 2 / 40
| Name | Price | % Change | |
|---|---|---|---|
| $7.13 | -67.51% | ||
| $7.12 | +47.11% |

Olema Oncology (OLMA) announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive, or ER+, human epidermal growth factor receptor 2-negative, or HER2-, breast cancer models. The

Puma Biotechnology (($PBYI)) has held its Q3 earnings call. Read on for the main highlights of the call. Puma Biotechnology’s third-quarter call carried a broadly positive tone, led by higher

Olema Pharmaceuticals ( ($OLMA) ) just unveiled an update. On November 12, 2026, the company changed its corporate name from Olema Pharmaceuticals, Inc. to Olema Oncology, Inc., after filing an

Goldman Sachs lowered the firm’s price target on Olema Oncology (OLMA) to $13 from $18 and keeps a Buy rating on the shares following the Q3 results. Goldman sees a

“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine

Olema Pharmaceuticals, Inc. (OLMA) is scheduled to report 3rd quarter earnings on 11/10/2026. Regarding Q3 estimates, Wall Street analysts expect Olema Pharmaceuticals, Inc. to post earnings of -$0.64 per share.

“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and

Olema Pharmaceuticals ( ($OLMA) ) has shared an update. On October 12, 2026, Olema Pharmaceuticals, Inc. announced that Dr. Gorjan Hrustanovic had resigned from its Board of Directors, effective October

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Olema Pharmaceuticals, with a price target of $36.00. Emily Bodnar has given his Buy rating

Puma Biotechnology ($PBYI) announced an update on their ongoing clinical study. Puma Biotechnology, Inc. (PBYI) is running a Phase 2 study called “A Phase 2 Study of Alisertib in Combination
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 10, 2026 | ||||
| hold | Reiterated | Aug 7, 2026 | ||||
| buy | Assigned | Nov 10, 2026 | ||||
| buy | Reiterated | Sep 21, 2026 | ||||
| buy | Reiterated | Sep 19, 2026 | ||||
| buy | Reiterated | Sep 14, 2026 | ||||
| buy | Reiterated | Sep 14, 2026 | ||||
| buy | Reiterated | Aug 20, 2026 | ||||
| buy | Reiterated | Aug 10, 2026 | ||||
| buy | Reiterated | Jun 2, 2026 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.